- Home
- NMCO vs DNTH Comparison
NMCO vs DNTH Comparison
Compare NMCO & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMCO
- DNTH
- Stock Information
- Founded
- NMCO 2019
- DNTH 2015
- Country
- NMCO United States
- DNTH United States
- Employees
- NMCO N/A
- DNTH N/A
- Industry
- NMCO Finance/Investors Services
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- NMCO Finance
- DNTH Health Care
- Exchange
- NMCO Nasdaq
- DNTH Nasdaq
- Market Cap
- NMCO 611.9M
- DNTH 711.2M
- IPO Year
- NMCO N/A
- DNTH N/A
- Fundamental
- Price
- NMCO $10.80
- DNTH $21.90
- Analyst Decision
- NMCO
- DNTH Strong Buy
- Analyst Count
- NMCO 0
- DNTH 9
- Target Price
- NMCO N/A
- DNTH $46.43
- AVG Volume (30 Days)
- NMCO 207.6K
- DNTH 285.9K
- Earning Date
- NMCO 01-01-0001
- DNTH 11-07-2024
- Dividend Yield
- NMCO 5.43%
- DNTH N/A
- EPS Growth
- NMCO N/A
- DNTH N/A
- EPS
- NMCO N/A
- DNTH N/A
- Revenue
- NMCO N/A
- DNTH $5,366,000.00
- Revenue This Year
- NMCO N/A
- DNTH $100.14
- Revenue Next Year
- NMCO N/A
- DNTH N/A
- P/E Ratio
- NMCO N/A
- DNTH N/A
- Revenue Growth
- NMCO N/A
- DNTH 51.41
- 52 Week Low
- NMCO $8.52
- DNTH $14.82
- 52 Week High
- NMCO $11.64
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- NMCO 55.05
- DNTH 45.58
- Support Level
- NMCO $10.60
- DNTH $18.72
- Resistance Level
- NMCO $10.89
- DNTH $28.65
- Average True Range (ATR)
- NMCO 0.11
- DNTH 2.24
- MACD
- NMCO 0.04
- DNTH -0.22
- Stochastic Oscillator
- NMCO 87.80
- DNTH 33.20
About NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.